PubMed Health⌕ Search

PubMed · 495622

Reimbursable pharmacy teaching program for adrenalectomy patients.

Abstract

A three-step, pharmacist-taught education program for adrenalectomy patients is described. Twenty-three patients were trained during the two years of the project. Training included: (1) an explanation of the patient's disease state and need for supplementary medication; (2) an explanation of each medication taken; and (3) training on self-administration of an i.m. dose of dexamethasone. Blue Cross agreed to pay the hospital ø25 per patient trained. Thirteen patients were available for interviews designed to evaluate the program. All patients knew the signs and symptoms of adrenal crisis and had excellent recall of information about their medication. Eight patients had increased their oral steroid doses as instructed to avoid adrenal insufficiency during stress. Substantial cost savings resulted from the program. The costs saved by offering the program justified the cost of supplying the service.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

R Schad, P J Schneider, E G Nold. 1979. Reimbursable pharmacy teaching program for adrenalectomy patients.. https://pubmed.ncbi.nlm.nih.gov/495622/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Rituximab for treatment of opsoclonus-myoclonus syndrome in neuroblastoma.

Opsoclonus-myoclonus syndrome (OMS) is a rare paraneoplastic syndrome that occurs in 2%-3% of patients with neuroblastoma. The cause of this syndrome is believed to be immune mediated, but the exact mechanism still remains unclear. There is an urgent need to improve our current strategies for treating patients with OMS, as many patients have significant long-term neurologic deficits and behavior disorders with current treatment approaches. Therapies that have shown to improve symptoms in these patients have ranged from ACTH and corticosteroids, to intravenous gammaglobulin and plasmapheresis. We report our experience with Rituximab in a patient with neuroblastoma and OMS.

Adrenal Cortex Hormones↗

Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study.

Although the calcineurin inhibitors (CNI) cyclosporine (CsA) and tacrolimus are highly effective immunosuppressants, they are associated with serious side effects. There is great interest in immunosuppressive regimens that permit reduction or elimination of CNIs, while maintaining adequate immunosuppression and acceptable acute rejection rates. Patients (n = 536) receiving their first renal allograft were randomized to one of three immunosuppressant regimens: daclizumab, mycophenolate mofetil (MMF), corticosteroids (CS) and low-dose CsA (target trough levels of 50-100 ng/mL), weaned from month 4 and withdrawn by month 6; daclizumab, MMF, CS and low-dose CsA; or MMF, CS and standard-dose CsA. Mean GFR 12 months after transplantation (primary end point) was not statistically different in the CsA withdrawal and low-dose CsA groups (both 50.9 mL/min/1.73 m(2)) vs. the standard-dose CsA group (48.6 mL/min/1.73 m(2)). At 12 months, the incidence of biopsy-proven acute rejection was significantly higher in the CsA withdrawal group (38%) vs. the low- or standard-dose CsA groups (25.4% and 27.5%, respectively; p < 0.05). In summary, a regimen of continuous low-dose CsA with MMF, CS and daclizumab induction is a clinically safe and effective immunosuppressive regimen in renal transplant recipients.

Adrenal Cortex Hormones↗